Advertisement

Pharmaceutical Chemistry Journal

, Volume 46, Issue 11, pp 639–646 | Cite as

5-Ht6 Receptor Antagonists. V. Structure – Activity Relationship of (4-Phenylsulfonyloxazol-5-yl)amines

  • A. V. Ivachtchenko
  • E. S. Golovina
  • M. G. Kadieva
  • O. D. Mitkin
  • I. M. Okun
Article

Both novel and previously reported (4-phenylsulfonyloxazol-5-yl)amine derivatives containing a substituted sulfonyl group were studied in order to discover highly active 5-HT6 receptor antagonists. A new pharmacophore model of 5-HT6 receptor antagonists was proposed based on the structure—5-HT6 antagonist activity relationship. It was established that the activity of the synthesized compounds depended strongly on the nature of the amine located vicinal to the sulfonyl. The most active ligands were methyl-(4-phenylsulfonyloxazol-5-yl)amines. Replacing the methyl by a bulkier alkyl radical and conversion to tertiary amines was accompanied by a dramatic reduction of their activity for 5-HT6 receptors.

Keywords

(4-phenylsulfonyloxazol-5-yl)amines sulfonyl group activity, serotonin receptors antagonists structure—activity pharmacophore model conformations stabilization 

References

  1. 1.
    A. V. Ivachtchenko, Y. A. Ivanenkov, and S. E. Tkachenko, Expert Opin. Ther. Pat., 20(7), 1247 – 1257 (2010).Google Scholar
  2. 2.
    W. J. Geldenhuys and C. J. Van der Schyf, Expert Rev. Neurother., 9(7), 1073 – 1085 (2009).PubMedCrossRefGoogle Scholar
  3. 3.
    D. J. Heal, S. L. Smith, A. Fisas, et al., Pharmacol. Ther., 117(2), 207 – 231 (2008).PubMedCrossRefGoogle Scholar
  4. 4.
    A. V. Ivachtchenko, D. E. Dmitriev, E. S. Golovina, et al., J. Med. Chem., 53(14), 5186 – 5196 (2010).PubMedCrossRefGoogle Scholar
  5. 5.
    F. Borsini (ed.), Pharmacology of 5-HT 6 receptors, Part I, Int. Rev. Neurobiol., Academic Press, (2010), p. 95.Google Scholar
  6. 6.
    M. L. Lopez-Rodriguez, B. Benhamu, T. de la Fuente, et al., J. Med. Chem., 48(13), 4216 – 4219 (2005).PubMedCrossRefGoogle Scholar
  7. 7.
    A. V. Ivashchenko, E. S. Golovina, O. D. Mit?kin, et al., in: New Directions in the Chemistry of Heterocyclic Compounds [in Russian], Materials of the Second International Scientific Conference, Grafa, Stavropol? (2011), p. 159.Google Scholar
  8. 8.
    A. V. Ivachtchenko, E. S. Golovina, M. G. Kadieva, et al., Bioorg. Med. Chem. Lett., 22(13), 4273 – 4280 (2012).PubMedCrossRefGoogle Scholar
  9. 9.
    K. G. Liu and A. J. Robichaud, Drug Dev. Res., 70, 145 – 168 (2009).CrossRefGoogle Scholar
  10. 10.
    A. V. Ivachtchenko, D. E. Dmitriev, E. S. Golovina, et al., Bioorg. Med. Chem. Lett., 20(7), 2133 – 2136 (2010).PubMedCrossRefGoogle Scholar
  11. 11.
    A. V. Ivachtchenko, E. S. Golovina, M. G. Kadieva, et al., Eur. J. Med. Chem., 46, 1189 – 1197 (2011).PubMedCrossRefGoogle Scholar
  12. 12.
    A. V. Ivachtchenko, E. S. Golovina, M. G. Kadieva, et al., Bioorg. Med. Chem., 19(4), 1482 – 1491 (2011).PubMedCrossRefGoogle Scholar
  13. 13.
    A. V. Ivashchenko, E. S. Golovina, and O. D. Mit?kin, in: Progress in Synthesis and Complexation [in Russian], Abstracts of Papers of the All-Russian Scientific Conference with International Participation Dedicated to the International Year of Chemistry, April 18 – 22, 2011, RUDN, Moscow (2011).Google Scholar
  14. 14.
    A. V. Ivachtchenko, E. S. Golovina, M. G. Kadieva, et al., J. Med. Chem., 54, 8161 – 8173 (2011).PubMedCrossRefGoogle Scholar
  15. 15.
    A. V. Ivashchenko, E. S. Golovina, M. G. Kadieva, et al., Khim.-farm. Zh., 46(5), 48 – 58 (2012).Google Scholar
  16. 16.
    H. Greiner, G. Bartoszyk, H. Boettcher, et al., Pat. WO2002 / 100842.Google Scholar
  17. 17.
    R. Gericke, H. Bottcher, M. Gassen, and H. Greiner, Pat. WO2001 / 28316.Google Scholar
  18. 18.
    H. Greiner, G. Bartoszyk, H. Boettcher, et al., Pat. WO2000 / 037452.Google Scholar
  19. 19.
    V. A. Chervonnyi, A. V. Kharchenko, and B. S. Drach, Zh. Org. Khim., 34(2), 453 – 454 (1988).Google Scholar
  20. 20.
  21. 21.
    I. M. Okun, S. E. Tkachenko, A. Khvat, et al., Curr. Alzheimer Res., 7(2), 97 – 112 (2010).PubMedCrossRefGoogle Scholar
  22. 22.
  23. 23.
    C. Reimer, E. Borroni, B. Levet-Trafit, et al., J. Med. Chem., 46(7), 1273 – 1276 (2003).CrossRefGoogle Scholar
  24. 24.
    N. Upton, T. T. Chuang, A. J. Hunter, and D. J. Virley, Neurotherapeutics, 5(3), 458 – 469 (2008).PubMedCrossRefGoogle Scholar
  25. 25.
    Y. Cheng and W. H. Prusoff, Biochem. Pharmacol., 22, 3099 – 3108 (1973).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • A. V. Ivachtchenko
    • 1
    • 2
  • E. S. Golovina
    • 1
  • M. G. Kadieva
    • 1
  • O. D. Mitkin
    • 1
  • I. M. Okun
    • 2
  1. 1.Chemical Diversity Research InstituteKhimki, Moscow OblastRussia
  2. 2.ChemDiv Inc.San DiegoUnited States

Personalised recommendations